<DOC>
	<DOCNO>NCT01658436</DOCNO>
	<brief_summary>This Phase II study 2 stage , evaluate BEZ235 plus best supportive care ( BSC ) versus placebo plus BSC patient advance pancreatic neuroendocrine tumor ( pNET ) failure mTOR inhibitor therapy . Study design : This Phase II , two-stage , multicenter study , Stage 1 single arm , open label design Stage 2 plan randomize , double-blind study . However , end Stage 1 , futility meet hence Stage 2 initiate .</brief_summary>
	<brief_title>BEZ235 Phase II Trial Patients With Advanced Pancreatic Neuroendocrine Tumors ( pNET ) After Failure mTOR Inhibitor Therapy .</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Adenoma , Islet Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Unresectable metastatic , histologically confirm low intermediate grade pancreatic neuroendocrine tumor radiological evidence disease progression since last treatment Refractory disease treatment mTOR inhibitor Measurable disease per RECIST Version 1.1 use Computed Tomography ( CT ) Magnetic Resonance Imaging ( MRI ) Prior concurrent therapy SSA permit ; stable dose least 2 month prior study start must continue stable dose receive study treatment ; SSA consider systemic treatment . WHO PS â‰¤ 1 Adequate bone marrow function organ function Previous treatment PI3K AKT inhibitor Discontinuation prior mTOR inhibitor therapy due toxicity Poorly differentiate neuroendocrine carcinoma , highgrade neuroendocrine carcinoma , adenocarcinoid , goblet cell carcinoid small cell carcinoma Radiotherapy , major surgery within 4 week prior study treatment start Hepatic artery embolization cryoablation/ radiofrequency ablation hepatic metastasis within 2 month study treatment start . More 3 prior systemic treatment regimen ( include cytotoxic chemotherapy , target therapy , immunotherapy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>advanced pancreatic neuroendocrine tumor</keyword>
	<keyword>BEZ235</keyword>
	<keyword>pNET</keyword>
</DOC>